Jukka Tapaninen is the Chief Executive Officer (CEO) of Aiforia. Before joining the company, he held various executive positions over the past 25 years in international IT and software businesses, such as SAP and HP. His experience includes leading enterprise software sales for healthcare industries as well as overseeing global business development, building strategic partnerships, and scaling up growth companies. He holds an M.Sc. degree in Economics.
Jukka Tapaninen Chief Executive Officer (CEO)
Kaisa Helminen is the Chief Operating Officer (COO) of Aiforia. Kaisa joined Aiforia in 2014 and has previously worked for international companies Sartorius, Thermo Fisher Scientific Inc., and a Finnish biotech company Finnzymes Oy. Kaisa has a strong background in the life science sector, where she has gained almost 20 years of experience in the global business. She has a wealth of experience in global sales, marketing, and strategic product management in life science businesses. She holds an M.Sc. degree in Biochemistry.
Kaisa Helminen Chief Operating Officer (COO)
.png?width=440&height=600&name=Antti%20Ojala_2%20(1).png)
Antti Ojala is the Chief Financial Officer (CFO) and a member of the Management Team at Aiforia. He has over 15 years of versatile experience in financial management, specifically within the health technology and diagnostics sectors. Antti joins Aiforia from Aurevia Oy, where he served as CFO, and he previously led financial operations at Mobidiag Oy. He has a strong track record in strategic financing and investor relations. Antti holds two Master’s degrees, in Economics and Engineering (M.Sc. Econ., M.Sc. Eng.).
Antti Ojala Chief Financial Officer (CFO)
Panu Kauppila is the Chief Product Officer (CPO) of Aiforia, playing a key role in defining Aiforia's product portfolio and prioritizing product development. He has more than 25 years of experience in productization and management of innovation in the medical technology sector in international companies. Thus, Panu has a profound understanding of how, with strong technological expertise, scalable products can be built on top of a software platform for demanding preclinical and clinical use. He holds M.Sc. in Technology.
Panu Kauppila Chief Product Officer (CPO)
Thomas Rosqvist is the Chief Technology Officer (CTO) of Aiforia. Rosqvist has over 15 years of diverse experience in leading software product development and solution architectures. He joined Aiforia from Tietoevry, where he has led Tietoevry Create’s strategic AI program and advised organizations on AI and technology strategies. Earlier in his career, he has held key expert and leadership roles, including at Accenture, and participated in healthcare technology projects. He holds an MSc in Software Engineering and an eMBA.
Thomas Rosqvist Chief Technology Officer (CTO)
Tuomas Tenkanen, M.Sc. in Technology, is currently the President and Managing Director of TJT Technologies Oy. He has an extensive background in life science and healthcare technologies.
Tuomas Tenkanen Chair of the Board of Directors
Joe has extensive experience in the life sciences and healthcare industries, having held senior leadership positions at BioIVT, Thermo Fisher Scientific, Siemens, and Abbott. He currently serves on the boards of StatLab and Rarity Biosciences and is an operating partner at Linden Capital Partners.
Joseph Bernardo Vice Chair of the Board of Directors
Johan is one of the co-founders of Aiforia as well as a Research Director at the Finnish Institute for Molecular Medicine (FIMM) at University of Helsinki and Professor of Medical Technology at Karolinska Institute.
Johan Lundin, MD, PhD Board Member
Jerry Jian Hong, MBA is currently the CEO of Ascend Capital, Managing Director Ascend Tapio/Artemis S.a.r.L, since 2020. He holds over 12 years experiences in sourcing, global project management, OEM sales and marketing and in addition he has over 10 years experience in business development focusing on overseas M&A and strategic development at the executive level.
Jerry Jian Hong, MBA Board Member
Minna has a strong business development, legal, and IP background in the life science industry, with experience in leadership and strategic initiatives. She has worked in various roles for companies such as Hologic International, Mobidiag, Kemira, Thermo Fisher Scientific, and Finnzymes.
Minna Koivula Board Member
Prof. Zlobec is a distinguished figure in the field of Digital Pathology, serving as Professor of Digital Pathology at the Institute of Tissue Medicine and Pathology, University of Bern in Switzerland. She leads an interdisciplinary research group focusing on improving the understanding of cancer biology and developing tools to address clinically relevant issues for patients. With a background in histopathology and biostatistics, Prof. Zlobec has collaborated closely with pathologists, clinicians, and scientists for over two decades.
Professor Inti Zlobec Institute of Tissue Medicine and Pathology, University of Bern in Switzerland
Dr. Bui is a Professor of Pathology and the Scientific Director of Analytic Microscopy Core at Moffitt Cancer Center in the United States. She was the President of the Digital Pathology Association in 2019. She is recognized as an impactful leader in pathology. Dr. Bui's expertise ranges from sarcoma pathology, cytopathology, digital pathology, and cancer biomarker testing.
Marilyn Bui, MD, PhD Moffitt Cancer Center
Richard is board certified in veterinary pathology (FRCPath, DipECVP) and toxicology (Diplomate of the American Board of Toxicology). He qualified in veterinary medicine from the University of Cambridge and completed a PhD at Oxford in experimental pathology and immunology. Richard has senior leadership experience in pharma at AstraZeneca and GSK, and he is the founder of RosettaPath, a science-based pathology consultancy.
Richard Haworth, PhD RosettaPath Ltd.
Dr. Yagi is the Director of Pathology Digital Imaging at Memorial Sloan Kettering Cancer Center (MSKCC) in New York in the United States. She received her PhD from Tokyo Medical University in Japan and soon after won a Nikon Fellowship for two research years in teleradiology and pathology at Georgetown University, Washington, D.C. in the United States.
Yukako Yagi, PhD Memorial Sloan Kettering Cancer Center
Professor Knowles is a global opinion leader in personalized medicine. He is currently a visiting Professor in Personalized Health Care at FIMM (Institute for Molecular Medicine Finland) at the University of Helsinki and a visiting Professor at the University of Oxford, UK. He also serves on the boards of a number of biotech companies and major academic centres. Most notably he was the President of Group Research for the Roche Group for 12 years until 2010 and more recently the Chairman of the Board of both Adaptimmune Ltd and Immunocore Ltd.
Jonathan Knowles, PhD Institute for Molecular Medicine Finland and University of Oxford